Randomized Trialhigh evidence
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.
JAMA·June 2, 2026·PMID 42099212
Why it mattersThis trial addresses a key clinical question in late-window stroke management: whether bridging thrombolysis adds benefit before EVT in patients with salvageable tissue. The neutral result suggests that in EVT-capable centers, tenecteplase may not improve functional outcomes in this time window.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled